Growth hormones

Pharmaceutical Biotechnology: Fundamentals and Applications, Third Edition

Volumn , Issue , 2016, Pages 281-291

  Marian, Melinda ^a   Oeswein, James Q ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84903800404     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (58)

1. Allen DB, Carrel AL (2004). Growth hormone therapy for Prader-Willi syndrome: a critical appraisal. J Ped Endocrinol Metab 17:1297-306.
2. Baumann G (1991). Growth hormone heterogeneity: Genes, isohormones, variants and binding proteins. Endoc. Rev 12:424-49.
3. Boguszewski CL (2003). Molecular heterogeneity of human GH: from basic research to clinical implications. J Endocrinol Invest 26:274-88.
4. Bouillon R (1991). Growth hormone and bone. Horm Res 36 (Suppl 1): 49-55.
5. Brook CGD, Hindmarsh PC (1992). The somatotropic axis in puberty. Endocrinol Metab Clin N Am 21:767-82.
6. Burgess E, Wanke C (2005). Use of recombinant human growth hormone in HIV-associated lipodystrophy. Curr Opin Infect Dis 18:17-24.
7. Cameron DP, Burger HG, Catt KJ, et al. (1972). Metabolic clearance of human growth hormone in patients with hepatic and renal failure, and in the isolated perfused pig liver. Metab 21:895-904.
8. Carroll PV, van den Berghe G (2001). Safety aspects of pharmacological GH therapy in adults. Growth Horm IGF Res 11:166-72.
9. Casanueva F (1992). Physiology of growth hormone secretion and action. Endocrin. Metab Clin N Am 21:483-517.
10. Colao A, Vitale G, Pivonello R, et al. (2004). The heart: an end-organ of GH action. Eur J Endocrinol 151:S93-101.
11. Fisker S (2006). Physiology and pathophysiology of growth hormone binding protein: methodological and clinical aspects. Growth Horm IGF Res 16:1-28.
12. Giustina A, Veldhuis JD (1998). Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and in the human. Endocrinol Rev 19(6):717-97.
13. Goeddel DV, Heyreker HL, Hozumi T, et al. (1979). Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone. Nature 281:544-8.
14. Greenbaum LA, Del Rio M, Bamgbola F, et al. (2004) Rationale for growth hormone therapy in children with chronic kidney disease. Adv Chronic Kidney Dis 11(4): 377-86.
15. Growth Hormone Research Society (2001). Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 86(15): 1868-70.
16. Hansen TK (2002). Pharmacokinetics and acute lipolytic actions of growth hormone: impact of age, body composition, binding proteins and other hormones. Growth Horm IGF Res 12:342-58.
17. Hardin DS (2004). GH improves growth and clinical status in children with cystic fibrosis-a review of published studies. Eur J Endocrinol 151:S81-5.
18. Harris M, Hofman PL, Cutfield WS (2004). Growth hormone treatment in children. Pediatr Drugs 6(2):93-106.
19. Harvey S (1995). Growth hormone metabolism. In: Harvey S, Scanes CG, Daughaday WH, eds. Growth Hormone. Boca Raton, FL: CRC Press, Inc, 285-301.
20. Herington AC, Ymer S, Stevenson J (1986). Identification and characterization of specific binding proteins for growth hormone in normal human sera. J Clin Invest 77:1817-23.
21. Herndon DN, Tompkins RG (2004). Support of the metabolic response to burn injury. Lancet 363:1895-902.
22. Herrington J, Carter-Su C (2001). Signaling pathways activated by the growth hormone receptor. Trends Endocrinol Metab 12(6):252-7.
23. Hintz RL, Rosenfeld RG, Wilson DM, et al. (1982). Biosynthetic methionyl human growth hormone is biologically active in adult man. Lancet 1:1276-9.
24. Iglesias P, Diez JJ (1999). Clinical applications of recombinant human growth hormone in adults. Expert Opin Pharmacother 1(1):97-107.
25. Isaksson OG, Ohlsson C, Bengtsson B, et al. (2000). GH and bone-experimental and clinical studies. Endocrin J 47 (Suppl):S9-16.
26. Jeevanandam M, Ali MR. Holaday NJ, et al. (1995). Adjuvant recombinant human hormone normalizes plasma amino acids in parenterally fed trauma patients. J Parenter Enteral Nutr 19:137-44.
27. Jorgensen JOL (1991). Human growth hormone replacement therapy: pharmacological and clinical aspects. Endocrinol Rev 12:189-207.
28. Keating GM, Wellington K (2004). Somatropin (ZorbtiveTM) in short bowel syndrome. Drugs 64(12):1375-81.
29. Kojima M, Hosoda H, Matsuo H, et al. (2001). Ghrelin:discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab 12(3):118-26.
30. Laursen T (2004). Clinical pharmacological aspects of growth hormone administration. Growth Horm IGF Res 14:16-44.
31. Le Roith D, Adamo M, Werner H, Roberts Jr CT (1991). Insulin-like growth factors and their receptors as growth regulators in normal physiology and pathologic states. Trends Endocrinol Metab 2:134-9.
32. Lewis UJ, Sinhda YN, Lewis GP (2000). Structure and properties of members of the hGH family: a review. Endocr J 47:S1-8.
33. Martial JA, Hallewell RA, Baxter JD (1979). Human growth hormone: complementary DNA cloning and expression in bacteria. Science 205:602-7.
34. Mauras N, Attie KM, Reiter EO, et al. (2000). High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases nearfinal height: a randomized, multicenter trial. J Clin Endocrinol Metab 85:3653-60.
35. McHugh CM, Park RT, Sonksen PH, et al. (2005). Challenges in detecting the abuse of growth hormone in sport. Clin Chem 51(9):1587-93.
36. Mertani HC, Delehaye-Zervas MC, Martini JF, et al. (1995). Localization of growth hormone receptor messenger RNA in human tissues. Endocrine 3:135-42.
37. Owens D, Srivastava MC, Tompkins CV, et al. (1973). Studies on the metabolic clearance rate, apparent distribution space and plasma half-disappearance time of unlabelled human growth hormone in normal subjects and in patients with liver disease, renal disease, thyroid disease and diabetes mellitus. Europ J Clin Invest 3:284-94.
38. Pasquino AM (2004). Turner syndrome and GH treatment:the state of the art. J Endocrinol Invest 27:1072-5.
39. Piwien-Pilipuk G, Huo JS, Schwartz J (2002). Growth hormone signal transduction. J Ped Endocrinol Metab 15:771-86.
40. Ponting GA, Halliday D, Teale JD, et al. (1988). Postoperative positive nitrogen balance with intravenous hyponutrition and growth hormone. Lancet 1:438-40.
41. Raben MS (1958). Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 18:901-3.
42. Rappaport R (2004). Growth and growth hormone in children born small for gestational age. Growth Horm IGF Res 14:S3-6.
43. Simpson H, Savine R, Sonksen P, et al. (2002). Growth hormone replacement therapy for adults: into the new millennium. Growth Horm IGF Res 12:1-33.
44. Sklar CA, Mertens AC, Mitby P, et al. (2002). Risk of disease recurrence and second neoplasms in survivors of children cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 87(7):3136-41.
45. Slonim AE, Bulone L, Damore MB, et al. (2000). A preliminary study of growth hormone therapy for Crohn's disease. New Engl J Med 342:1633-7.
46. Society (2001). Critical evaluation of the safety of recombinant human growth hormone administration: Statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 86(5):1868-70.
47. Strobl JS, Thomas MJ (1994). Human growth hormone. Pharm Rev 46:1-34.
48. Takala J, Ruokonen E, Webster NR, et al. (1999). Increased mortality associated with growth hormone treatment in critically ill adults. New Engl J Med 341(11):785-92.
49. Theiss AL, Fruchtman S, Lund PK (2004). Growth factors in inflammatory bowel disease. The actions and interactions of growth hormone and insulin-like growth factor-I. Inflamm Bowel Dis 10(6):871-80.
50. Voerman BJ, Strack van Schijndel RJM, Goreneveld ABJ, et al. (1995). Effects of human growth hormone in critically ill non-septic patients: results from a prospective, randomized, placebo-controlled trial. Crit Care Med 23:665-73.
51. Wells JA, Cunningham BC, Fuh G, et al. (1993). The molecular basis for growth hormone-receptor interactions. Rec Prog Horm Res 48:253-75.
52. Boguszewski CL (2003). Molecular heterogeneity of human GH: from basic research to clinical implications. J Endocrinol Invest 26:274-88.
53. Fisker S (2006). Physiology and pathophysiology of growth hormone binding protein: methodological and clinical aspects. Growth Horm IGF Res 16:1-28.
54. Giustina A, Veldhuis JD (1998). Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and in the human. Endocrinol Rev 19(6):717-97.
55. Harvey S, Scanes CG, Daughaday WH, eds. (1995). Growth Hormone. Boca Raton, FL: CRC Press, Inc.
56. Harris M, Hofman PL, Cutfield WS (2004). Growth hormone treatment in children. Pediatr Drugs 6(2):93-106.
57. Laursen T (2004). Clinical pharmacological aspects of growth hormone administration. Growth Horm IGF Res 14:16-44.
58. Simpson H, Savine R, Sonksen P, et al. (2002). Growth hormone replacement therapy for adults: into the new millennium. Growth Horm IGF Res 12:1-33.